Performed in a single session without any surgical incisions or scarring, the treatment utilizes an advanced fusion-guided ...

Profound Medical Corp. (NASDAQ:PROF) Q4 2025 Earnings Call Transcript March 6, 2026 Operator: Good day, and thank you for ...

The Radioligand Therapy Market is projected to reach US$13 billion by 2030, growing at an estimated rate of 5%. Key drivers of this growth include the rising incidence of cancers such as prostate ...

Jessica Lougeay-Benson and her husband, David, had just moved their family to Minnesota from Colorado. Having first met at Concordia Language Villages, the couple sought to relocate ...

Innoblative Designs, Inc. (Innoblative), a private medical device company addressing clinical unmet needs for patients with breast cancer, announced today that it has received Category III Current ...

Telix Pharmaceuticals reports positive Phase 3 safety results for its investigational prostate cancer therapy, TLX591-Tx. The post Telix Pharmaceuticals reports positive TLX591-Tx Phase 3 results ...

Telix reported FY2025 revenue of $804M, up 56% YoY, with Precision Portfolio products Illuccix and Gozellix contributing $622M. Read why TLX stock is a Buy.

Nuclear fusion group SHINE Technologies said it has raised $240 million in equity funding to advance the company's commercial ...

Telix Pharmaceuticals focuses on radiopharmaceuticals for the diagnosis and treatment of cancer.

SHINE Technologies, a nuclear fusion company, today announced it has raised $240 million in equity funding, and appointed Dr. Patrick Soon-Shiong, M.D., Executive Chairman of ImmunityBio and founder ...

CEOCFO interviews NanOlogy, LLC CEO David J. Arthur on Solving Toxicity & Bioavailability Problems when Treating ...

The global medical cyclotron market shows steady growth, expected to be valued at around US$246.8 million in 2026 and projected to reach US$405.4 million by 2033, with a CAGR of 5.4% during this ...